Description

Emerging therapeutics based on gene addition, editing, or silencing are expected to change the landscape of genetic liver disease.

Watch this episode to find out:

• Which approaches exist?
• Where are they in terms of preclinical and clinical development?
• How will they be used?

Faculty

• Dr Mattias Mandorfer (Moderator)
• Dr Gloria Gonzalez-Aseguinolaza (Faculty)
• Prof. Pavel Strnad (Faculty)
• Prof. Man-Fung Yuen (Faculty)

ℹ️ Please click here to access the podcast version of this EASL Studio episode.